GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (LTS:0KC7) » Definitions » Profitability Rank

OncoSec Medical (LTS:0KC7) Profitability Rank : 1 (As of Jan. 2023)


View and export this data going back to 2018. Start your Free Trial

What is OncoSec Medical Profitability Rank?

OncoSec Medical has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

OncoSec Medical's Operating Margin % for the quarter that ended in Jan. 2023 was %. As of today, OncoSec Medical's Piotroski F-Score is 0.


Competitive Comparison of OncoSec Medical's Profitability Rank

For the Biotechnology subindustry, OncoSec Medical's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSec Medical's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's Profitability Rank distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's Profitability Rank falls into.



OncoSec Medical Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

OncoSec Medical has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

OncoSec Medical's Operating Margin % for the quarter that ended in Jan. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Jan. 2023 ) / Revenue (Q: Jan. 2023 )
=-7.664 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

OncoSec Medical has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


OncoSec Medical Profitability Rank Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSec Medical (LTS:0KC7) Business Description

Traded in Other Exchanges
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

OncoSec Medical (LTS:0KC7) Headlines

No Headlines